BackProtagonist Therapeutics Overview

Protagonist Therapeutics Receivables

Protagonist Therapeutics's receivables is $13M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$13.42M

Peer trimmed avg / median

Loading

Protagonist Therapeutics Receivables History

Loading

Protagonist Therapeutics vs. peers: Receivables Comparison

Loading

Protagonist Therapeutics Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Protagonist Therapeutics (PTGX) FAQ

As of the most recent data (June 2026), PTGX shows a receivables of $13M. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, PTGX's receivables is now $13M (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Protagonist Therapeutics is outperforming or lagging.

Tracking PTGX's receivables over time shows whether Protagonist Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $13M In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Protagonist Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $13M) with ownership activity and broader fundamentals.

Protagonist Therapeutics's receivables is $13M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.